Home » Archives by category » Clinical Trial News
Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102

Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102

Denovo Biopharma has secured approval from the US Food and Drug Administration (FDA) to launch its phase 2b clinical trial of DB102 in patients with newly-diagnosed glioblastoma (GBM) in combination with radiation and temozolomide. The GBM clinical study is an extension of the company’s work to identify a genetically-enriched patient population with diffuse large B-cell […]

DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial

Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate, in wet age-related macular degeneration (wet AMD). The DAZZLE trial (also called KSI-CL-102) is designed to assess the safety and efficacy of KSI-301 in AMD patients who are treatment-naïve. […]

Continue reading …
Kangpu wraps up phase 1 clinical trial of CRL4-CRBN modulator KPG-818

Chinese pharma company Kangpu Biopharmaceuticals said that it has wrapped up the first-in-human phase 1 clinical trial of CRL4-CRBN modulator KPG-818 in the US. KPG-818 is being developed for the treatment of systemic lupus erythematosus (SLE) or hematological malignancies. The single ascending dose (SAD) randomized, double-blind, placebo-controlled study assessed the safety, tolerability, and pharmacokinetics of […]

Continue reading …
Galderma launches phase 3 atopic dermatitis trial for nemolizumab

Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment of moderate-to-severe atopic dermatitis. The late-stage clinical trial will feature adult patients, who are randomly grouped in a double-blinded, placebo-controlled study that will assess the efficacy and safety of the […]

Continue reading …
CENTAUR clinical trial of AMX0035 : Amylyx says last patient completes last study visit

Amylyx Pharmaceuticals said that the last enrolled patient in the CENTAUR clinical trial, which is evaluating AMX0035 for amyotrophic lateral sclerosis (ALS), has finished the 24 weeks of study treatment. The CENTAUR clinical study is a randomized, double-blind, placebo-controlled phase 2 clinical trial. The primary goals of the mid-stage clinical trial are to assess the […]

Continue reading …
Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD

Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-stage pharma company engaged in developing drugs for ocular diseases like wet AMD, diabetic macular edema (DME), primary open […]

Continue reading …
JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo

Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]

Continue reading …
Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment

US biopharma company Catabasis Pharmaceuticals has wrapped up enrollment for the phase 3 PolarisDMD clinical trial designed to evaluate edasalonexent, an NF-kB inhibitor, in Duchenne muscular dystrophy (DMD). The biopharma company said that the target enrollment of 125 boys was surpassed owing to strong interest from its 40 clinical sites across eight countries along with […]

Continue reading …
CinDome Pharma begins phase 2 trial of gastroparesis drug CIN-102

US biotech company CinDome Pharma has enrolled the first patient in a phase 2 clinical trial which will evaluate its investigational gastroparesis drug deuterated domperidone (CIN-102). Considered to be a debilitating, chronic condition, gastroparesis impacts the stomach muscles and leads to improper emptying of the stomach. Deuterated domperidone (CIN-102), which has been developed through deuteration […]

Continue reading …
FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint

FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]

Continue reading …
Page 1 of 9123Next ›Last »